Objectives and outcomes in the conventional treatment of pediatric Crohn's disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 33, Issue SUPPL. 1, 2001, Pages

  Buller H A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PLACEBO; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED DRUG RELEASE; CROHN DISEASE; DIARRHEA; DIET THERAPY; DRUG EFFICACY; DRUG MEGADOSE; ENTERIC FEEDING; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0034785637     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200109001-00003     Document Type: Conference Paper

References (65)

1. National Cooperative Crohn's Disease Study: Results of drug treatment
2. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
3. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease
4. The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial
5. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa
6. 111 in granulocyte excretion
7. Slow-release 5-aminosalycylic acid (Pentasa) for the treatment of active Crohn's disease
8. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
9. Medical therapy for inflammatory bowel disease
10. Medical therapy for Crohn's disease
11. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Arasol, in the treatment of symptomatic Crohn's colitis and ileocolitis
12. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: Results of a randomized multicenter trial
13. Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance
14. A randomized, placebocontrolled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease
15. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. Placebo in the maintenance of remission of patients with Crohn's disease
16. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease
17. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease. A multicenter placebo-controlled study
18. Mesalazine (Pentasa) as prophylaxis in Crohn's disease. A multicenter, controlled trial
19. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables
20. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI
21. The pharmacology of anti-inflammatory drugs in inflammatory bowel disease
22. Semi-elemental (S-E) diet vs prednisone in pediatric Crohn's disease
23. Oral budesonide for active Crohn's disease
24. A comparison of budesonide and mesalamine for active Crohn's disease
25. A comparison of budesonide with prednisolone for active Crohn's disease
26. Oral budesonide is as effective as oral prednisolone in active Crohn's disease
27. Corticosteroids for maintaining remission of Crohn's disease (Cochrane Review)
28. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study
29. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease
30. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: A multicentre randomized placebo-controlled trial
31. Oral budesonide as maintenance therapy in Crohn's diseaseresults of a 12-month study
32. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study
33. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease
34. Management of complications of glucocorticosteroid therapy
35. Growth suppression of glucocorticoid therapy
36. Users of low-dose glucocorticoids have increased bone loss rates: A longitudinal study
37. Metabolic bone disease in adults with inflammatory bowel disease
38. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease
39. Relationship of type I procollagen to corticosteroid therapy in children with inflammatory bowel disease
40. Glucocorticoid-induced osteoporosis: Pathogenesis and management
41. Double blind, placebo controlled trial of metronidazole in Crohn's disease
42. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study
43. Metronidazole in Crohn's disease. A double-blind cross-over clinical trial
44. Healing of perianal Crohn's disease with metronidazole
45. Metronidazole therapy for perianal Crohn's disease: A follow-up study
46. Peripheral neuropathy in Crohn's disease patients treated with metronidazole
47. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis
48. Azathioprine in the treatment of children with inflammatory bowel disease
49. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease
50. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease
51. Methotrexate for the treatment of Crohn's disease
52. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
53. Methotrexate in patients with Crohn's disease after 6-mercaptopurine
54. Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children
55. Treatment of Crohn's disease with 6-mercaptopurine
56. A controlled double blind study of azathioprine in the management of Crohn's disease
57. 6-Mercaptopurine in the management of inflammatory bowel disease: Short-and longterm toxicity
58. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease
59. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease
60. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease
61. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease
62. Controlled trial of polymeric versus elemental diet in treatment of active Crohn's disease
63. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: Elemental versus polymeric diet
64. Polymeric versus elemental diet as primary treatment in active Crohn's disease: A randomized, double-blind trial